The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $20,301,030 in first-year total cost, median $1,358,275.
Most frequent study sections
- Special Emphasis Panel[ZAI1 LR-M (M2)]16
Most frequent institutions
- ALBERT EINSTEIN COLLEGE OF MEDICINE, INC1
- BROAD INSTITUTE, INC.1
- CURZA INC1
- FZATA, INC.1
- GENEVA FOUNDATION1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | New targets against tuberculosis1R01AI132300-01 | HUNG, DEBORAH T | BROAD INSTITUTE, INC., MA | $1,505,690 | ZAI1 |
| 2017 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection1R01AI132207-01 | FENG, HANPINGYANG, ZHIYONG | FZATA, INC., MD | $1,460,626 | ZAI1 |
| 2017 | Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV1R01AI132178-01 | BARIC, RALPH SSHEAHAN, TIMOTHY PATRICK | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,455,240 | ZAI1 |
| 2017 | A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics1R01AI132256-01 | CHANDRAN, KARTIKLAI, JONATHAN R. | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY | $1,452,650 | ZAI1 |
| 2017 | Preclinical Development of a Thermostable Trivalent Filovirus Vaccine1R01AI132323-01 | LEHRER, AXEL T | UNIVERSITY OF HAWAII AT MANOA, HI | $1,437,310 | ZAI1 |
| 2017 | Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae1R01AI132276-01 | ARON, ZACHARY DAVID | MICROBIOTIX, INC, MA | $1,432,109 | ZAI1 |
| 2017 | An Advanced Vaccine Candidate To Prevent Zika Virus Infection1R01AI132186-01 | SLIFKA, MARK K | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $1,394,457 | ZAI1 |
| 2017 | An Avirulent Arthroconidial Vaccine Candidate to Prevent Human Coccidioidomycosis1R01AI132140-01 | GALGIANI, JOHN N | UNIVERSITY OF ARIZONA, AZ | $1,371,202 | ZAI1 |
| 2017 | Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever1R01AI132246-01 | GEISBERT, THOMAS WILLIAM | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $1,345,347 | ZAI1 |
| 2017 | Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail1R01AI132223-01 | GARRY, ROBERT F | TULANE UNIVERSITY OF LOUISIANA, LA | $1,268,148 | ZAI1 |
| 2017 | Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea1R01AI132296-01 | RAM, SANJAYRICE, PETER A.WYCOFF, KEITH | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $1,250,425 | ZAI1 |
| 2017 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’1R01AI132154-01 | LI, JIANVELKOV, TONY | MONASH UNIVERSITY | $1,059,804 | ZAI1 |
| 2017 | Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease1R01AI132313-01 | HOOPER, JAY WILLIAMS | GENEVA FOUNDATION, WA | $1,037,264 | ZAI1 |
| 2017 | Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND1R01AI132191-01 | GLENN, JEFFREY S | STANFORD UNIVERSITY, CA | $1,000,000 | ZAI1 |
| 2017 | Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 1221R01AI132257-01 | BARRY, EILEEN M.CHEN, WILBUR H. | UNIVERSITY OF MARYLAND BALTIMORE, MD | $963,769 | ZAI1 |
| 2017 | Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome1R01AI132304-01 | TESTA, CHARLES | CURZA INC, UT | $866,989 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.